Drug Trial Radar · NCT06733935
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Nov 4, 2024
Primary completion
Oct 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Nkarta, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
Conditions
- Systemic Sclerosis
- Idiopathic Inflammatory Myopathies
- Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
- Rheumatoid Arthritis
Interventions
NKX019Drug
NKX019 is an investigational allogeneic CD19-Directed CAR NK
FludarabineDrug
Lymphodepletion
CyclophosphamideDrug
Lymphodepletion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-limiting toxicities (DLTs) [Safety and Tolerability]Time frame: The first 28 days after the first NKX019 dose
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: From the first administration of NKX019 until the last administration of any study treatment + 30 days
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Nkarta Investigational Site
Los Angeles, California · Recruiting
Nkarta Investigational Site
Plantation, Florida · Recruiting
Nkarta Investigational Site
Tampa, Florida · Recruiting
Nkarta Investigational Site
Fairway, Kansas · Recruiting
Nkarta Investigational Site
Ann Arbor, Michigan · Recruiting
Nkarta Investigational Site
Minneapolis, Minnesota · Recruiting
Nkarta Investigational Site
Hackensack, New Jersey · Recruiting
Nkarta Investigational Site
Summit, New Jersey · Recruiting
Nkarta Investigational Site
New York, New York · Recruiting
Nkarta Investigational Site
Syracuse, New York · Recruiting
Nkarta Investigational Site
Charlotte, North Carolina · Recruiting
Nkarta Investigational Site
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.